Clinuvel

Clinuvel Pharmaceuticals Ltd is an Australian biopharmaceutical company developing an innovative photoprotective pharmaceutical drug under the generic name afamelanotide (INN by WHO). Clinuvel is headquartered in Melbourne, and has offices in Zürich and is currently expanding its presence to New Jersey. Clinuvel's focus is to gain market approval for afamelanotide to manage the symptoms of severe sufferers of various UV and light related skin disorders. The global team at Clinuvel is excited and committed at the prospect of being able to treat patients who have not been able to receive effective medicinal relief.

The drug used by Clinuvel is proprietary and is based on advanced technology developed over more than a decade of further research by the company. Clinuvel aims to enter the phase of commercialization in 2009, pending regulatory review worldwide.

Clinuvel is working globally with a large number of leading academic centers to develop afamelanotide to obtain market authorization. Safety and efficacy of the drug are the main variables being monitored worldwide.